Saltar al contenido
Merck

SML1522

Sigma-Aldrich

Doxofylline

≥98% (HPLC)

Sinónimos:

7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione, 7-(1,3-Dioxolan-2-ylmethyl)theophylline

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C11H14N4O4
Número de CAS:
Peso molecular:
266.25
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

Nivel de calidad

Ensayo

≥98% (HPLC)

Formulario

powder

color

white to beige

solubilidad

H2O: 2 mg/mL, clear (warmed)

temp. de almacenamiento

2-8°C

cadena SMILES

CN1C2=C(N(CC3OCCO3)C=N2)C(N(C)C1=O)=O

InChI

1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3

Clave InChI

HWXIGFIVGWUZAO-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Doxofylline is a novel xanthine derivative comprising of dioxolone group.

Aplicación

Doxofylline has been used as a phosphodiesterase (PDE) inhibitor to study its protective effects on lipopolysaccharides (LPS)-induced inflammatory response in human pulmonary bronchial epithelial cells. It has also been used to study its interaction with bovine serum albumin (BSA).

Acciones bioquímicas o fisiológicas

Doxofylline (also known as doxophylline) has antitussive and bronchodilator effects. Doxofylline is used clinically in the treatment of asthma. Doxofylline has similar efficacy to theophylline, but unlike theophylline or other xanthines has little affinity for adenosine receptors and does not produce stimulant effects and has significantly fewer side effects.
Doxofylline acts and as a non-selective phosphodiesterase (PDE) inhibitor and exhibits anti-inflammatory activity. It has the potential to treat chronic obstructive pulmonary disease (COPD).

Pictogramas

Exclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sami Manzoor Margay et al.
Journal of clinical and diagnostic research : JCDR, 9(4), FC05-FC08 (2015-05-30)
Asthma is a non communicable chronic disease prevalent all over the world. Two commonly used methylxanthines, theophylline and doxofylline were compared in the study in stable asthmatic patients at recommended doses by various spirometric lung function tests with forced expiratory
Muhasaparur Ganesan Rajanandh et al.
Clinical therapeutics, 37(2), 418-426 (2015-01-13)
Data comparing various second-line treatments for asthma with subjective and objective assessment are lacking. This study aimed to compare the efficacy and safety of montelukast, doxofylline, and tiotropium with a low-dose budesonide in patients with mild to moderate persistent asthma.
Dushyant Lal et al.
Journal of basic and clinical physiology and pharmacology, 26(5), 443-451 (2015-04-22)
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients. The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with
R Cirillo et al.
Archives internationales de pharmacodynamie et de therapie, 295, 221-237 (1988-09-01)
In the present study the interaction of doxofylline, a new antiasthmatic drug, with A1- and A2-adenosine receptors of the guinea-pig brain and rat striatum was investigated in comparison with known methylxanthine derivatives. Inhibition studies of N6-cyclohexyl-3H-adenosine (3H-CHA), 1,3-diethyl-8-3H-phenylxanthine (3H-DPX) binding
Sokratis Katsikas et al.
Studies in health technology and informatics, 134, 113-125 (2008-04-01)
The health care sector is quickly exploiting Information and Communication Technologies towards the provision of e-health services. According to recent surveys, one of the most severe restraining factors for the proliferation of e-health is the (lack of) security measures required

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico